Interview: OliPass An Oligonucleotide Outsider With Big Ambitions
Executive Summary
South Korean bioventure OliPass tells Scrip how it intends to grab a leading position in the global antisense oligonucleotide drug sector using in-house developed technology that it says can both sharply lower prices and increase safety in the field, where it is initially focusing on novel pain therapies.
You may also be interested in...
Korean Biotech Sentiment Still Shaky But IPO Recovery Seen By Year-End
After a lackluster year so far for South Korean biotech IPOs amid disappointing clinical trial news, investor interest is beginning to pick up, with several companies that have been under the spotlight slated to debut on the market in the coming months.
Incentives, Novel Tech Seen Driving Multiple Korean IPOs In 2018
Despite an expected absence of large floats like that of Celltrion Healthcare last year, IPOs by biotech and pharma firms in South Korea are poised to rise in 2018 amid an improved stock listing environment and progress in novel drug development.
Finance Watch: Seed/Series A Financings Benefit As Big Crossover Rounds Slow
Silicon Valley Bank data show a pullback in crossover financings but an increase in seed and series A venture capital rounds. In recent private company financings, CRO Novotech raised $760m. In public company financings, Eleusis will merge with a SPAC and the Bausch + Lomb IPO is on file with the SEC.